Have a feature idea you'd love to see implemented?
Let us know!
MTEM Molecular Templates Inc
Price (delayed)
$0.1072
Market cap
$705,792
P/E Ratio
0.21
Dividend/share
N/A
EPS
$0.51
Enterprise value
-$561,208
Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Its proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the
Highlights
MTEM's equity has soared by 182% YoY and by 21% from the previous quarter
MTEM's net income has soared by 67% YoY and by 15% QoQ
The EPS has surged by 144% since the previous quarter but it has dropped by 96% year-on-year
The company's revenue fell by 49% YoY and by 20% QoQ
MTEM's gross profit is down by 49% year-on-year and by 20% since the previous quarter
Key stats
What are the main financial stats of MTEM
Market
Valuations
Earnings
Shares outstanding
6.58M
Market cap
$705,792
Enterprise value
-$561,208
Price to earnings (P/E)
0.21
Price to book (P/B)
0.1
Price to sales (P/S)
0.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.02
Revenue
$25.47M
Gross profit
$25.47M
Net income
-$15.63M
EBIT
-$15.5M
EBITDA
-$10.63M
Free cash flow
-$23.92M
Per share
Balance sheet
Liquidity
EPS
$0.51
EPS diluted
$0.48
Free cash flow per share
-$3.65
Book value per share
$1.08
Revenue per share
$3.88
TBVPS
$4.07
Total assets
$26.7M
Total liabilities
$19.59M
Debt
$8.39M
Equity
$7.11M
Working capital
$4.34M
Debt to equity
1.18
Current ratio
1.56
Quick ratio
1.36
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-41.7%
Gross margin
100%
Net margin
-61.4%
Operating margin
-74.3%
Return on assets
-46.9%
Return on equity
-260.5%
Return on invested capital
-86.1%
Return on capital employed
-81.5%
Return on sales
-60.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MTEM stock price
How has the Molecular Templates stock price performed over time
Intraday
-23.43%
1 week
-70.5%
1 month
-68.03%
1 year
-97.12%
YTD
-97.13%
QTD
-92.37%
Financial performance
How have Molecular Templates's revenue and profit performed over time
Revenue
$25.47M
Gross profit
$25.47M
Operating income
-$18.93M
Net income
-$15.63M
Gross margin
100%
Net margin
-61.4%
MTEM's net income has soared by 67% YoY and by 15% QoQ
The company's operating income has surged by 58% YoY and by 17% QoQ
The company's revenue fell by 49% YoY and by 20% QoQ
MTEM's gross profit is down by 49% year-on-year and by 20% since the previous quarter
Growth
What is Molecular Templates's growth rate over time
Valuation
What is Molecular Templates stock price valuation
P/E
0.21
P/B
0.1
P/S
0.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.02
The EPS has surged by 144% since the previous quarter but it has dropped by 96% year-on-year
MTEM's equity has soared by 182% YoY and by 21% from the previous quarter
MTEM's P/B is 98% below its 5-year quarterly average of 5.4 and 97% below its last 4 quarters average of 3.2
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 11.5 and 93% lower than the last 4 quarters average of 0.4
The company's revenue fell by 49% YoY and by 20% QoQ
Efficiency
How efficient is Molecular Templates business performance
MTEM's ROE has soared by 71% QoQ
The return on sales rose by 26% year-on-year but it has declined by 13% since the previous quarter
Molecular Templates's ROA has increased by 17% YoY and by 9% from the previous quarter
Molecular Templates's return on invested capital has decreased by 16% YoY but it has increased by 13% QoQ
Dividends
What is MTEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MTEM.
Financial health
How did Molecular Templates financials performed over time
Molecular Templates's total assets is 36% more than its total liabilities
Molecular Templates's quick ratio has surged by 62% QoQ
MTEM's total liabilities has dropped by 56% year-on-year and by 8% since the previous quarter
The debt is 18% more than the equity
MTEM's debt to equity has soared by 193% year-on-year but it is down by 24% since the previous quarter
MTEM's equity has soared by 182% YoY and by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.